• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于香豆素-咔唑的功能化吡唑啉:合成、表征、抗癌研究及分子对接

Coumarin-carbazole based functionalized pyrazolines: synthesis, characterization, anticancer investigation and molecular docking.

作者信息

Patel Mrugesh, Pandey Nilesh, Timaniya Jignesh, Parikh Paranjay, Chauhan Alex, Jain Neeraj, Patel Kaushal

机构信息

Department of Advanced Organic Chemistry, P. D. Patel Institute of Applied Sciences, Charotar University of Science and Technology Gujarat 388421 India

Department of Medical Laboratory Technology, Charotar Institute of Paramedical Sciences, Charotar University of Science and Technology Gujarat 388421 India

出版信息

RSC Adv. 2021 Aug 13;11(44):27627-27644. doi: 10.1039/d1ra03970a. eCollection 2021 Aug 9.

DOI:10.1039/d1ra03970a
PMID:35480680
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9037808/
Abstract

A series of novel pyrazoline scaffolds from coumarin-carbazole chalcones were synthesized. We explored various acetyl, amide, and phenyl substituents at the -1 position of the pyrazoline core. The synthesized compounds were characterized by FTIR, H-NMR, C-NMR, DEPT, and mass spectroscopic techniques. The cytotoxicity study of all the synthesized compounds was evaluated against HeLa, NCI-H520 and NRK-52E cell lines. Compounds 4a and 7b became the most active compounds and exhibited their potential to arrest the cell cycle progression and induce apoptosis in both the cell lines. In addition, molecular docking studies revealed a higher binding affinity of both the molecules with CDK2 protein. Based on the obtained results, a comprehensive analysis is warranted to establish the role of compounds 4a and 7b as promising cancer therapeutic agents.

摘要

合成了一系列基于香豆素 - 咔唑查尔酮的新型吡唑啉支架。我们在吡唑啉核心的 -1 位探索了各种乙酰基、酰胺基和苯基取代基。通过傅里叶变换红外光谱(FTIR)、氢核磁共振(H-NMR)、碳核磁共振(C-NMR)、无畸变极化转移增强法(DEPT)和质谱技术对合成的化合物进行了表征。对所有合成化合物针对人宫颈癌HeLa细胞系、人非小细胞肺癌NCI-H520细胞系和大鼠肾细胞NRK-52E细胞系进行了细胞毒性研究。化合物4a和7b成为活性最高的化合物,并显示出在两个细胞系中阻滞细胞周期进程和诱导细胞凋亡的潜力。此外,分子对接研究表明这两种分子与细胞周期蛋白依赖性激酶2(CDK2)蛋白具有更高的结合亲和力。基于所获得的结果,有必要进行全面分析以确定化合物4a和7b作为有前景的癌症治疗药物的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/fd0b4d7e9a6f/d1ra03970a-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/a75e5ccbcda8/d1ra03970a-s1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/21b10bbacb5f/d1ra03970a-s2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/9bde0cd073d0/d1ra03970a-s3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/ac9bcd91712f/d1ra03970a-s4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/6f4ee066114a/d1ra03970a-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/bfff19d09515/d1ra03970a-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/024350441903/d1ra03970a-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/8395edad800c/d1ra03970a-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/01de4fd6fc85/d1ra03970a-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/3b7eedabe239/d1ra03970a-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/fd0b4d7e9a6f/d1ra03970a-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/a75e5ccbcda8/d1ra03970a-s1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/21b10bbacb5f/d1ra03970a-s2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/9bde0cd073d0/d1ra03970a-s3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/ac9bcd91712f/d1ra03970a-s4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/6f4ee066114a/d1ra03970a-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/bfff19d09515/d1ra03970a-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/024350441903/d1ra03970a-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/8395edad800c/d1ra03970a-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/01de4fd6fc85/d1ra03970a-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/3b7eedabe239/d1ra03970a-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a979/9037808/fd0b4d7e9a6f/d1ra03970a-f7.jpg

相似文献

1
Coumarin-carbazole based functionalized pyrazolines: synthesis, characterization, anticancer investigation and molecular docking.基于香豆素-咔唑的功能化吡唑啉:合成、表征、抗癌研究及分子对接
RSC Adv. 2021 Aug 13;11(44):27627-27644. doi: 10.1039/d1ra03970a. eCollection 2021 Aug 9.
2
New pyridine-based chalcones and pyrazolines with anticancer, antibacterial, and antiplasmodial activities.新型吡啶基查耳酮和吡唑啉类化合物具有抗癌、抗菌和抗疟原虫活性。
Arch Pharm (Weinheim). 2024 Jul;357(7):e2400081. doi: 10.1002/ardp.202400081. Epub 2024 Mar 28.
3
Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.新型吡唑啉类抗结核和细胞毒性药物的合成、生物学评价及分子对接研究
Infect Disord Drug Targets. 2019;19(3):310-321. doi: 10.2174/1871526519666181217120626.
4
Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.新型 2-(5-芳基-4,5-二氢吡唑-1-基)噻唑-4-酮作为 EGFR 抑制剂:合成、生物学评估和分子对接研究。
Drug Des Devel Ther. 2022 May 16;16:1457-1471. doi: 10.2147/DDDT.S356988. eCollection 2022.
5
Molecular Docking Study, Cytotoxicity, Cell Cycle Arrest and Apoptotic Induction of Novel Chalcones Incorporating Thiadiazolyl Isoquinoline in Cervical Cancer.新型查尔酮类硫代二唑并异喹啉衍生物的分子对接研究及其对宫颈癌的细胞毒性、细胞周期阻滞和凋亡诱导作用。
Anticancer Agents Med Chem. 2020;20(1):70-83. doi: 10.2174/1871520619666191024121116.
6
Pyrazoline analogs as potential anticancer agents and their apoptosis, molecular docking, MD simulation, DNA binding and antioxidant studies.吡唑啉类似物作为潜在的抗癌剂及其细胞凋亡、分子对接、MD 模拟、DNA 结合和抗氧化研究。
Bioorg Chem. 2021 Mar;108:104665. doi: 10.1016/j.bioorg.2021.104665. Epub 2021 Jan 27.
7
New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.新型噻唑-腙-香豆素杂合体靶向人宫颈癌细胞:合成、CDK2 抑制、QSAR 和分子对接研究。
Bioorg Chem. 2019 May;86:80-96. doi: 10.1016/j.bioorg.2019.01.026. Epub 2019 Jan 19.
8
Design and Synthesis of Carbothioamide/Carboxamide-Based Pyrazoline Analogs as Potential Anticancer Agents: Apoptosis, Molecular Docking, ADME Assay, and DNA Binding Studies.基于碳硫酰胺/羧酰胺的吡唑啉类似物作为潜在抗癌剂的设计与合成:细胞凋亡、分子对接、ADME 分析及 DNA 结合研究
ACS Omega. 2022 Jun 23;7(26):22639-22656. doi: 10.1021/acsomega.2c02033. eCollection 2022 Jul 5.
9
Novel cyanochalcones as potential anticancer agents: apoptosis, cell cycle arrest, DNA binding, and molecular docking studies.新型氰基查耳酮作为潜在的抗癌剂:细胞凋亡、细胞周期阻滞、DNA结合及分子对接研究
J Biomol Struct Dyn. 2024 Feb 19:1-19. doi: 10.1080/07391102.2024.2316764.
10
Synthesis, Cytotoxicity Evaluation, Molecular Docking and Utility of Novel Chalcones as Precursors for Heterocycles Incorporating Pyrazole Moiety.新型查尔酮作为含吡唑部分杂环前体的合成、细胞毒性评估、分子对接及应用
Med Chem. 2018;14(4):344-355. doi: 10.2174/1573406413666171020114105.

引用本文的文献

1
3,5-Disubstituted pyrazoline as a promising core for anticancer agents: mechanisms of action and therapeutic potentials.3,5-二取代吡唑啉作为一种有前景的抗癌药物核心结构:作用机制与治疗潜力
Future Med Chem. 2025 Mar;17(6):725-745. doi: 10.1080/17568919.2025.2476393. Epub 2025 Mar 13.
2
Latest developments in coumarin-based anticancer agents: mechanism of action and structure-activity relationship studies.基于香豆素的抗癌剂的最新进展:作用机制及构效关系研究
RSC Med Chem. 2023 Oct 20;15(1):10-54. doi: 10.1039/d3md00511a. eCollection 2024 Jan 25.
3
Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective.

本文引用的文献

1
Design, synthesis and biological evaluation of -arylsulfonyl carbazoles as novel anticancer agents.新型抗癌药物——芳基磺酰基咔唑的设计、合成及生物学评价
RSC Adv. 2018 May 10;8(31):17183-17190. doi: 10.1039/c8ra02939c. eCollection 2018 May 9.
2
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.泽布替尼治疗复发或难治性套细胞淋巴瘤。
Blood Adv. 2021 Jun 22;5(12):2577-2585. doi: 10.1182/bloodadvances.2020004074.
3
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
含氮杂环作为抗癌剂:药物化学视角
Pharmaceuticals (Basel). 2023 Feb 14;16(2):299. doi: 10.3390/ph16020299.
4
A Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization.靶向微管蛋白聚合的分子杂化物的最新进展综述
Int J Mol Sci. 2022 Apr 4;23(7):4001. doi: 10.3390/ijms23074001.
《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
4
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer.香豆素类及其相关化合物在癌症药物治疗中的应用
Cancers (Basel). 2020 Jul 19;12(7):1959. doi: 10.3390/cancers12071959.
5
Synthesis, characterization, antimicrobial and DNA binding properties of an organic charge transfer complex obtained from pyrazole and chloranilic acid.由吡唑和氯冉酸合成、表征的有机电荷转移配合物及其抗菌和 DNA 键合性质。
Bioorg Chem. 2020 Jun;99:103779. doi: 10.1016/j.bioorg.2020.103779. Epub 2020 Mar 20.
6
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.克唑替尼治疗含有 MET 外显子 14 改变的肺癌的抗肿瘤活性。
Nat Med. 2020 Jan;26(1):47-51. doi: 10.1038/s41591-019-0716-8. Epub 2020 Jan 13.
7
Design, synthesis and molecular docking of benzophenone conjugated with oxadiazole sulphur bridge pyrazole pharmacophores as anti inflammatory and analgesic agents.苯甲酮与含硫桥的噁二唑吡唑药效团的共轭物的设计、合成及分子对接:作为抗炎和镇痛药。
Bioorg Chem. 2019 Nov;92:103220. doi: 10.1016/j.bioorg.2019.103220. Epub 2019 Aug 26.
8
Carbazole scaffolds in cancer therapy: a review from 2012 to 2018.咔唑骨架在癌症治疗中的应用:2012 年至 2018 年的综述。
J Enzyme Inhib Med Chem. 2019 Dec;34(1):1321-1346. doi: 10.1080/14756366.2019.1640692.
9
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.克唑替尼治疗 ROS1 重排的晚期非小细胞肺癌(NSCLC):PROFILE 1001 研究的更新结果,包括总生存期。
Ann Oncol. 2019 Jul 1;30(7):1121-1126. doi: 10.1093/annonc/mdz131.
10
Design, synthesis, and apoptosis-promoting effect evaluation of novel pyrazole with benzo[d]thiazole derivatives containing aminoguanidine units.新型含氨基胍单元苯并[d]噻唑衍生物吡唑的设计、合成及诱导细胞凋亡活性评价。
J Enzyme Inhib Med Chem. 2019 Dec;34(1):829-837. doi: 10.1080/14756366.2019.1591391.